Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7Genitourinary 6Gastrointestinal 3Lymphoid 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1NET 1Myeloid 1Gynecologic 1Endocrine 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Central Nervous System Neoplasms 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Lomustine 36Ipilimumab 36Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × entinostat × CNS × Clear all
NCT03838042 2024-02-07

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

University Hospital Heidelberg

Phase 1/2 Recruiting
91 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡